| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratitis | 50 | 2010 | 104 | 4.960 |
Why?
|
| Eye Infections, Fungal | 29 | 2010 | 68 | 4.670 |
Why?
|
| Corneal Ulcer | 25 | 2010 | 56 | 4.150 |
Why?
|
| Keratitis, Herpetic | 18 | 2020 | 23 | 3.890 |
Why?
|
| Cornea | 57 | 2015 | 565 | 3.780 |
Why?
|
| Eye Infections, Bacterial | 25 | 2007 | 81 | 3.290 |
Why?
|
| Candidiasis | 19 | 2010 | 134 | 2.880 |
Why?
|
| Candida albicans | 16 | 2010 | 87 | 1.830 |
Why?
|
| Corneal Stroma | 17 | 2020 | 77 | 1.740 |
Why?
|
| Antiviral Agents | 19 | 2020 | 805 | 1.730 |
Why?
|
| Debridement | 10 | 2015 | 94 | 1.720 |
Why?
|
| Fungal Proteins | 7 | 2010 | 136 | 1.510 |
Why?
|
| Corneal Diseases | 14 | 2015 | 93 | 1.390 |
Why?
|
| Tissue Donors | 15 | 2011 | 503 | 1.260 |
Why?
|
| Endophthalmitis | 12 | 2008 | 48 | 1.230 |
Why?
|
| Eye Infections, Viral | 4 | 2020 | 24 | 1.180 |
Why?
|
| Acanthamoeba Keratitis | 8 | 2008 | 16 | 1.120 |
Why?
|
| Prednisolone | 10 | 2020 | 73 | 1.010 |
Why?
|
| Eye Banks | 9 | 2011 | 11 | 0.960 |
Why?
|
| Fungi | 9 | 2007 | 74 | 0.950 |
Why?
|
| Bacteria | 13 | 2007 | 521 | 0.940 |
Why?
|
| Glucocorticoids | 6 | 2020 | 347 | 0.930 |
Why?
|
| Probability | 5 | 2011 | 305 | 0.910 |
Why?
|
| Mycoses | 9 | 2010 | 110 | 0.890 |
Why?
|
| Administration, Topical | 21 | 2015 | 130 | 0.830 |
Why?
|
| Corneal Transplantation | 13 | 2007 | 44 | 0.810 |
Why?
|
| Keratitis, Dendritic | 14 | 2000 | 18 | 0.810 |
Why?
|
| Fusarium | 3 | 2010 | 14 | 0.800 |
Why?
|
| Keratoplasty, Penetrating | 15 | 2011 | 48 | 0.780 |
Why?
|
| Mice, Inbred BALB C | 15 | 2010 | 977 | 0.710 |
Why?
|
| Acyclovir | 15 | 2009 | 49 | 0.690 |
Why?
|
| Hyphae | 4 | 2010 | 8 | 0.680 |
Why?
|
| Gene Expression Regulation, Fungal | 3 | 2010 | 56 | 0.650 |
Why?
|
| Contact Lenses | 8 | 2008 | 39 | 0.610 |
Why?
|
| Gene Expression Regulation | 5 | 2010 | 2319 | 0.600 |
Why?
|
| Data Interpretation, Statistical | 3 | 2004 | 225 | 0.600 |
Why?
|
| Organ Preservation | 6 | 2011 | 62 | 0.570 |
Why?
|
| Endothelium, Corneal | 5 | 2011 | 27 | 0.570 |
Why?
|
| Humans | 159 | 2020 | 130511 | 0.560 |
Why?
|
| Disinfectants | 2 | 2015 | 27 | 0.530 |
Why?
|
| Contact Lens Solutions | 2 | 2015 | 5 | 0.510 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 1205 | 0.500 |
Why?
|
| Ophthalmic Solutions | 13 | 2020 | 86 | 0.490 |
Why?
|
| Ciprofloxacin | 3 | 2003 | 65 | 0.490 |
Why?
|
| Climate | 2 | 2006 | 23 | 0.480 |
Why?
|
| Graft Rejection | 6 | 2011 | 540 | 0.480 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2015 | 11 | 0.470 |
Why?
|
| Lubricant Eye Drops | 1 | 2015 | 12 | 0.470 |
Why?
|
| Visual Acuity | 16 | 2020 | 519 | 0.460 |
Why?
|
| Drug Therapy, Combination | 10 | 2011 | 1165 | 0.450 |
Why?
|
| Antiprotozoal Agents | 6 | 2008 | 41 | 0.440 |
Why?
|
| Bacterial Infections | 11 | 2007 | 327 | 0.440 |
Why?
|
| Polymers | 1 | 2015 | 103 | 0.440 |
Why?
|
| Middle Aged | 61 | 2020 | 28420 | 0.440 |
Why?
|
| Female | 85 | 2020 | 70545 | 0.420 |
Why?
|
| Disease Models, Animal | 12 | 2010 | 4646 | 0.420 |
Why?
|
| Fluoroquinolones | 3 | 2004 | 94 | 0.410 |
Why?
|
| Conjunctiva | 7 | 2003 | 196 | 0.410 |
Why?
|
| Trifluridine | 8 | 2020 | 10 | 0.410 |
Why?
|
| Virulence | 7 | 2010 | 268 | 0.410 |
Why?
|
| Gene Expression Profiling | 6 | 2009 | 1800 | 0.400 |
Why?
|
| Sclera | 5 | 2007 | 47 | 0.400 |
Why?
|
| Adult | 56 | 2020 | 31115 | 0.400 |
Why?
|
| Ascomycota | 2 | 2005 | 28 | 0.390 |
Why?
|
| Herpes Simplex | 1 | 2013 | 59 | 0.390 |
Why?
|
| Acanthamoeba | 5 | 2007 | 9 | 0.380 |
Why?
|
| Administration, Oral | 11 | 2015 | 709 | 0.380 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 190 | 0.380 |
Why?
|
| Eye Infections, Parasitic | 2 | 2007 | 8 | 0.380 |
Why?
|
| Male | 81 | 2020 | 64586 | 0.370 |
Why?
|
| Signal Transduction | 3 | 2010 | 4663 | 0.370 |
Why?
|
| Iris | 2 | 2008 | 36 | 0.360 |
Why?
|
| Anti-Infective Agents | 4 | 2003 | 265 | 0.360 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2010 | 992 | 0.360 |
Why?
|
| Aged | 50 | 2015 | 20897 | 0.360 |
Why?
|
| Models, Statistical | 2 | 2004 | 483 | 0.360 |
Why?
|
| Cataract Extraction | 7 | 2008 | 127 | 0.360 |
Why?
|
| Photomicrography | 2 | 2011 | 10 | 0.350 |
Why?
|
| Animals | 41 | 2010 | 33725 | 0.350 |
Why?
|
| Corneal Neovascularization | 3 | 2009 | 13 | 0.340 |
Why?
|
| Corneal Edema | 3 | 2004 | 9 | 0.340 |
Why?
|
| Confidence Intervals | 4 | 2008 | 270 | 0.340 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 1997 | 102 | 0.330 |
Why?
|
| beta-Defensins | 1 | 2010 | 12 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2015 | 1262 | 0.330 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 37 | 0.320 |
Why?
|
| Transcription Factors | 2 | 2010 | 2402 | 0.320 |
Why?
|
| DNA-Binding Proteins | 2 | 2010 | 1936 | 0.320 |
Why?
|
| Culture Media | 4 | 2006 | 169 | 0.310 |
Why?
|
| Proteoglycans | 1 | 2010 | 77 | 0.310 |
Why?
|
| Chemokines, CC | 1 | 2009 | 25 | 0.310 |
Why?
|
| Combined Modality Therapy | 7 | 2015 | 1211 | 0.310 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 38 | 0.310 |
Why?
|
| Aspergillus nidulans | 1 | 2009 | 27 | 0.310 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 4 | 2010 | 95 | 0.300 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 4 | 2004 | 82 | 0.300 |
Why?
|
| Aspergillosis | 1 | 2009 | 43 | 0.300 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 83 | 0.300 |
Why?
|
| Corneal Injuries | 3 | 2007 | 35 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 158 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2009 | 849 | 0.290 |
Why?
|
| Cysteine Endopeptidases | 1 | 2009 | 109 | 0.290 |
Why?
|
| Eyelid Diseases | 2 | 2006 | 58 | 0.290 |
Why?
|
| Vitreous Body | 3 | 2003 | 54 | 0.290 |
Why?
|
| Syphilis | 2 | 2006 | 95 | 0.290 |
Why?
|
| Eye Injuries | 3 | 2007 | 51 | 0.280 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 61 | 0.280 |
Why?
|
| Cataract | 2 | 2008 | 153 | 0.280 |
Why?
|
| Research | 2 | 2001 | 264 | 0.280 |
Why?
|
| Mice | 16 | 2010 | 18198 | 0.280 |
Why?
|
| Parasitology | 2 | 1998 | 7 | 0.270 |
Why?
|
| Prospective Studies | 17 | 2011 | 6424 | 0.270 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2002 | 298 | 0.270 |
Why?
|
| Ophthalmology | 4 | 2004 | 175 | 0.270 |
Why?
|
| Recurrence | 12 | 2013 | 1482 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 242 | 0.270 |
Why?
|
| Opportunistic Infections | 2 | 2006 | 69 | 0.260 |
Why?
|
| Orbital Diseases | 3 | 2006 | 64 | 0.260 |
Why?
|
| Functional Laterality | 1 | 2008 | 176 | 0.260 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 86 | 0.250 |
Why?
|
| Seasons | 3 | 2005 | 335 | 0.250 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 135 | 0.250 |
Why?
|
| Publishing | 3 | 2007 | 105 | 0.250 |
Why?
|
| Periodicals as Topic | 2 | 2007 | 182 | 0.240 |
Why?
|
| Organ Preservation Solutions | 2 | 2011 | 21 | 0.240 |
Why?
|
| Necrobiotic Disorders | 1 | 2006 | 2 | 0.240 |
Why?
|
| Xanthomatosis | 1 | 2006 | 8 | 0.240 |
Why?
|
| Amebiasis | 3 | 1994 | 11 | 0.240 |
Why?
|
| Scleritis | 1 | 2006 | 10 | 0.240 |
Why?
|
| Temperature | 2 | 2005 | 290 | 0.240 |
Why?
|
| Risk Factors | 18 | 2008 | 11011 | 0.240 |
Why?
|
| Genes, Fungal | 4 | 2010 | 57 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 12 | 2009 | 2580 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 587 | 0.230 |
Why?
|
| Strabismus | 2 | 2004 | 64 | 0.230 |
Why?
|
| Granuloma | 1 | 2006 | 59 | 0.230 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1123 | 0.230 |
Why?
|
| Postoperative Complications | 7 | 2008 | 3124 | 0.230 |
Why?
|
| Conjunctivitis | 6 | 2015 | 20 | 0.230 |
Why?
|
| Retrospective Studies | 21 | 2011 | 17650 | 0.230 |
Why?
|
| Keratoconjunctivitis | 3 | 2001 | 19 | 0.230 |
Why?
|
| Lateral Medullary Syndrome | 1 | 2004 | 3 | 0.220 |
Why?
|
| Vision, Low | 1 | 2004 | 12 | 0.220 |
Why?
|
| Interferons | 3 | 2015 | 138 | 0.210 |
Why?
|
| Drug Contamination | 2 | 2000 | 35 | 0.210 |
Why?
|
| Iridocyclitis | 2 | 1996 | 3 | 0.210 |
Why?
|
| Adolescent | 30 | 2015 | 20876 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1996 | 218 | 0.210 |
Why?
|
| Mycobacterium chelonae | 1 | 2003 | 4 | 0.200 |
Why?
|
| Head Movements | 1 | 2004 | 18 | 0.200 |
Why?
|
| Nystagmus, Pathologic | 1 | 2004 | 23 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 1445 | 0.200 |
Why?
|
| Benzamidines | 3 | 2008 | 9 | 0.200 |
Why?
|
| Aged, 80 and over | 12 | 2015 | 6772 | 0.200 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2003 | 45 | 0.200 |
Why?
|
| Posture | 1 | 2004 | 136 | 0.190 |
Why?
|
| Antifungal Agents | 6 | 2007 | 290 | 0.190 |
Why?
|
| Head | 1 | 2004 | 111 | 0.190 |
Why?
|
| Tattooing | 1 | 2002 | 6 | 0.190 |
Why?
|
| Microbiological Techniques | 3 | 2003 | 33 | 0.190 |
Why?
|
| Tissue and Organ Procurement | 4 | 2006 | 252 | 0.190 |
Why?
|
| Repressor Proteins | 1 | 2007 | 758 | 0.190 |
Why?
|
| Sex Characteristics | 1 | 2004 | 321 | 0.190 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2002 | 44 | 0.180 |
Why?
|
| Myopia | 3 | 2010 | 121 | 0.180 |
Why?
|
| Syphilis, Congenital | 1 | 2002 | 32 | 0.180 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2009 | 409 | 0.180 |
Why?
|
| Pseudomonas Infections | 4 | 1995 | 117 | 0.180 |
Why?
|
| Chlorhexidine | 3 | 2008 | 48 | 0.180 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 5185 | 0.180 |
Why?
|
| Time Factors | 13 | 2011 | 6169 | 0.170 |
Why?
|
| Cohort Studies | 7 | 2013 | 5048 | 0.170 |
Why?
|
| Double-Blind Method | 6 | 2020 | 1613 | 0.170 |
Why?
|
| Benzenesulfonates | 2 | 1994 | 12 | 0.170 |
Why?
|
| Irritants | 1 | 2001 | 8 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2001 | 148 | 0.170 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 266 | 0.170 |
Why?
|
| Toxicity Tests | 1 | 2001 | 34 | 0.170 |
Why?
|
| Journalism, Medical | 1 | 2001 | 8 | 0.170 |
Why?
|
| Amoeba | 2 | 1999 | 4 | 0.170 |
Why?
|
| Publications | 1 | 2001 | 36 | 0.170 |
Why?
|
| Capnocytophaga | 2 | 1994 | 6 | 0.170 |
Why?
|
| Vitrectomy | 3 | 2010 | 42 | 0.160 |
Why?
|
| Xanthenes | 1 | 2000 | 6 | 0.160 |
Why?
|
| Cysts | 3 | 1998 | 80 | 0.160 |
Why?
|
| Colorimetry | 1 | 2000 | 16 | 0.160 |
Why?
|
| Administration, Ophthalmic | 1 | 2020 | 7 | 0.160 |
Why?
|
| Oxazines | 1 | 2000 | 32 | 0.160 |
Why?
|
| Vibrio Infections | 1 | 2000 | 14 | 0.160 |
Why?
|
| Vibrio | 1 | 2000 | 9 | 0.160 |
Why?
|
| Aging | 2 | 2004 | 1237 | 0.160 |
Why?
|
| Contact Lenses, Hydrophilic | 4 | 2015 | 18 | 0.150 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 426 | 0.150 |
Why?
|
| Water Microbiology | 1 | 1999 | 26 | 0.150 |
Why?
|
| Eye | 4 | 2003 | 215 | 0.150 |
Why?
|
| Penicillin Resistance | 2 | 1998 | 81 | 0.150 |
Why?
|
| Family | 1 | 2002 | 587 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2007 | 2298 | 0.150 |
Why?
|
| Quality Control | 3 | 2007 | 116 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 3 | 1998 | 389 | 0.140 |
Why?
|
| Immunosuppressive Agents | 4 | 2007 | 652 | 0.140 |
Why?
|
| Keratoconus | 2 | 1998 | 51 | 0.140 |
Why?
|
| Water | 1 | 1999 | 185 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2004 | 561 | 0.140 |
Why?
|
| Pneumococcal Infections | 2 | 1998 | 280 | 0.140 |
Why?
|
| Colony Count, Microbial | 5 | 2007 | 86 | 0.140 |
Why?
|
| Rabbits | 12 | 2000 | 573 | 0.130 |
Why?
|
| Gram-Negative Bacteria | 2 | 1997 | 76 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2020 | 12851 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2010 | 826 | 0.130 |
Why?
|
| Body Temperature | 2 | 2007 | 126 | 0.120 |
Why?
|
| Xanthomonas | 1 | 1996 | 3 | 0.120 |
Why?
|
| Swine | 2 | 2010 | 1183 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2010 | 4699 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2001 | 1234 | 0.120 |
Why?
|
| Staining and Labeling | 2 | 1994 | 166 | 0.120 |
Why?
|
| Child | 20 | 2008 | 26233 | 0.120 |
Why?
|
| Antiparasitic Agents | 1 | 1996 | 28 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2010 | 3351 | 0.120 |
Why?
|
| Staphylococcal Infections | 4 | 1995 | 561 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 2 | 1996 | 220 | 0.110 |
Why?
|
| Hair | 1 | 1995 | 30 | 0.110 |
Why?
|
| Lipidoses | 1 | 1995 | 2 | 0.110 |
Why?
|
| DNA, Fungal | 4 | 2003 | 75 | 0.110 |
Why?
|
| Ganciclovir | 1 | 1995 | 101 | 0.110 |
Why?
|
| Tacrolimus | 1 | 1995 | 100 | 0.110 |
Why?
|
| Body Weights and Measures | 2 | 2004 | 33 | 0.110 |
Why?
|
| Genotype | 2 | 2010 | 2589 | 0.110 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 1995 | 63 | 0.100 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2014 | 4 | 0.100 |
Why?
|
| Capsulorhexis | 1 | 2014 | 3 | 0.100 |
Why?
|
| Glaucoma | 2 | 2008 | 73 | 0.100 |
Why?
|
| Viscosupplements | 1 | 2014 | 8 | 0.100 |
Why?
|
| Retinal Degeneration | 1 | 1995 | 84 | 0.100 |
Why?
|
| State Government | 1 | 1994 | 33 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 28 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2008 | 1208 | 0.100 |
Why?
|
| Tobramycin | 3 | 1987 | 22 | 0.100 |
Why?
|
| Trabeculectomy | 2 | 2008 | 11 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 2080 | 0.100 |
Why?
|
| Hyaluronic Acid | 1 | 2014 | 107 | 0.100 |
Why?
|
| Eye Diseases | 7 | 1987 | 106 | 0.100 |
Why?
|
| Guanine | 3 | 1982 | 58 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2002 | 68 | 0.100 |
Why?
|
| Biguanides | 2 | 2008 | 14 | 0.090 |
Why?
|
| Disease Progression | 2 | 2010 | 2192 | 0.090 |
Why?
|
| Phacoemulsification | 1 | 2014 | 134 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 410 | 0.090 |
Why?
|
| Amphotericin B | 3 | 2009 | 89 | 0.090 |
Why?
|
| Models, Biological | 3 | 2010 | 1371 | 0.090 |
Why?
|
| Registries | 3 | 2008 | 1614 | 0.090 |
Why?
|
| Ointments | 4 | 2003 | 13 | 0.090 |
Why?
|
| Corneal Opacity | 1 | 1991 | 21 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 723 | 0.090 |
Why?
|
| Photography | 2 | 2009 | 79 | 0.090 |
Why?
|
| Chickenpox | 1 | 1991 | 22 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 2897 | 0.080 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 188 | 0.080 |
Why?
|
| Cathelicidins | 1 | 2010 | 13 | 0.080 |
Why?
|
| Cryopreservation | 1 | 2011 | 78 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1069 | 0.080 |
Why?
|
| Reoperation | 3 | 2011 | 815 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 37 | 0.080 |
Why?
|
| Edema | 2 | 1989 | 129 | 0.080 |
Why?
|
| Herpesviridae Infections | 2 | 2000 | 147 | 0.080 |
Why?
|
| HIV Infections | 1 | 2002 | 2047 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2010 | 31 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 1987 | 1171 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2010 | 362 | 0.080 |
Why?
|
| Retinal Detachment | 1 | 2010 | 40 | 0.080 |
Why?
|
| Premedication | 3 | 2003 | 39 | 0.080 |
Why?
|
| Metalloproteases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Laser Therapy | 1 | 1992 | 243 | 0.080 |
Why?
|
| Syphilis Serodiagnosis | 2 | 2006 | 15 | 0.080 |
Why?
|
| Retinopathy of Prematurity | 1 | 2010 | 65 | 0.080 |
Why?
|
| Genome, Fungal | 1 | 2009 | 33 | 0.080 |
Why?
|
| Adenoviridae Infections | 2 | 1987 | 75 | 0.070 |
Why?
|
| Laser Coagulation | 1 | 2010 | 114 | 0.070 |
Why?
|
| Zinc Fingers | 1 | 2009 | 116 | 0.070 |
Why?
|
| Paecilomyces | 1 | 2009 | 4 | 0.070 |
Why?
|
| Acridine Orange | 1 | 1988 | 3 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2009 | 20 | 0.070 |
Why?
|
| Phenazines | 1 | 1988 | 9 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 3038 | 0.070 |
Why?
|
| Gentian Violet | 1 | 1988 | 8 | 0.070 |
Why?
|
| Child, Preschool | 10 | 2010 | 15028 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 3815 | 0.070 |
Why?
|
| Streptococcus | 1 | 1989 | 64 | 0.070 |
Why?
|
| Uveitis, Anterior | 3 | 1985 | 5 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 371 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 645 | 0.070 |
Why?
|
| Leukocytes | 1 | 2009 | 205 | 0.070 |
Why?
|
| Fluorescent Dyes | 2 | 1986 | 246 | 0.070 |
Why?
|
| Kinetics | 2 | 2009 | 1087 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 316 | 0.070 |
Why?
|
| Eyelids | 3 | 1997 | 105 | 0.070 |
Why?
|
| Eye Infections | 1 | 2008 | 3 | 0.070 |
Why?
|
| United States | 8 | 2008 | 12009 | 0.070 |
Why?
|
| Microscopy | 1 | 2009 | 118 | 0.070 |
Why?
|
| Vision, Binocular | 1 | 2008 | 29 | 0.070 |
Why?
|
| Dacryocystitis | 2 | 2000 | 22 | 0.070 |
Why?
|
| Epithelium | 4 | 1996 | 334 | 0.070 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2014 | 186 | 0.070 |
Why?
|
| Conjunctivitis, Allergic | 1 | 1987 | 18 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2002 | 348 | 0.070 |
Why?
|
| Cyanoacrylates | 1 | 1987 | 13 | 0.070 |
Why?
|
| Connective Tissue Diseases | 1 | 1987 | 32 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 324 | 0.070 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 1987 | 39 | 0.070 |
Why?
|
| Atrophy | 1 | 2008 | 247 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2008 | 71 | 0.060 |
Why?
|
| Conjunctivitis, Viral | 1 | 1987 | 1 | 0.060 |
Why?
|
| Bibliometrics | 1 | 2007 | 37 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 405 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2007 | 63 | 0.060 |
Why?
|
| Antigens, Bacterial | 1 | 1989 | 318 | 0.060 |
Why?
|
| Cellulitis | 3 | 1996 | 63 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2007 | 107 | 0.060 |
Why?
|
| Incidence | 3 | 2007 | 3336 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2007 | 218 | 0.060 |
Why?
|
| Conjunctivitis, Inclusion | 1 | 1986 | 1 | 0.060 |
Why?
|
| Maxillary Diseases | 1 | 1986 | 2 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 229 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2009 | 767 | 0.060 |
Why?
|
| Myiasis | 1 | 1986 | 5 | 0.060 |
Why?
|
| Adenovirus Infections, Human | 1 | 1987 | 60 | 0.060 |
Why?
|
| Interferon Type I | 1 | 1987 | 118 | 0.060 |
Why?
|
| Cell Movement | 1 | 2009 | 875 | 0.060 |
Why?
|
| Humidity | 1 | 2005 | 26 | 0.060 |
Why?
|
| Herpes Zoster Ophthalmicus | 4 | 1987 | 11 | 0.060 |
Why?
|
| Brain Abscess | 1 | 1986 | 54 | 0.060 |
Why?
|
| Infectious Mononucleosis | 2 | 1986 | 13 | 0.060 |
Why?
|
| HIV | 1 | 1987 | 174 | 0.060 |
Why?
|
| Uveitis | 3 | 1987 | 33 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2007 | 307 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2004 | 142 | 0.060 |
Why?
|
| Cytophagaceae | 1 | 1985 | 1 | 0.060 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 84 | 0.060 |
Why?
|
| Idoxuridine | 2 | 1982 | 5 | 0.060 |
Why?
|
| RNA | 1 | 2008 | 514 | 0.060 |
Why?
|
| Muramidase | 1 | 1985 | 37 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2004 | 293 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 117 | 0.050 |
Why?
|
| Horse Diseases | 1 | 1985 | 36 | 0.050 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2004 | 15 | 0.050 |
Why?
|
| Medulla Oblongata | 1 | 2004 | 24 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2004 | 89 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 2003 | 101 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2002 | 1243 | 0.050 |
Why?
|
| Antigens, Viral | 3 | 2000 | 395 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 397 | 0.050 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1985 | 71 | 0.050 |
Why?
|
| Retinoscopy | 1 | 2004 | 8 | 0.050 |
Why?
|
| Methylcellulose | 1 | 1984 | 3 | 0.050 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 1984 | 13 | 0.050 |
Why?
|
| Chemical Precipitation | 1 | 2003 | 10 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2544 | 0.050 |
Why?
|
| Refractive Errors | 1 | 2004 | 58 | 0.050 |
Why?
|
| Crystallization | 1 | 2003 | 83 | 0.050 |
Why?
|
| Diplopia | 1 | 2004 | 45 | 0.050 |
Why?
|
| Cause of Death | 3 | 2008 | 502 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 1332 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 4 | 1991 | 331 | 0.050 |
Why?
|
| Drainage | 2 | 1998 | 246 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 1983 | 44 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 89 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 1986 | 208 | 0.050 |
Why?
|
| Prognosis | 3 | 2007 | 4866 | 0.050 |
Why?
|
| Random Allocation | 4 | 1995 | 409 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1984 | 176 | 0.050 |
Why?
|
| Scedosporium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Gentamicins | 2 | 2000 | 88 | 0.050 |
Why?
|
| Observer Variation | 1 | 2004 | 311 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2003 | 304 | 0.050 |
Why?
|
| Decision Trees | 1 | 2003 | 57 | 0.050 |
Why?
|
| Bacterial Typing Techniques | 1 | 2003 | 97 | 0.050 |
Why?
|
| Models, Economic | 1 | 2003 | 59 | 0.050 |
Why?
|
| Drug Costs | 1 | 2003 | 66 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2003 | 234 | 0.050 |
Why?
|
| Phenylephrine | 2 | 2004 | 35 | 0.040 |
Why?
|
| Aqueous Humor | 2 | 2001 | 16 | 0.040 |
Why?
|
| Triazoles | 1 | 2003 | 141 | 0.040 |
Why?
|
| Dry Eye Syndromes | 1 | 2006 | 295 | 0.040 |
Why?
|
| Linear Models | 1 | 2003 | 687 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2009 | 3819 | 0.040 |
Why?
|
| Glaucoma, Open-Angle | 2 | 1992 | 26 | 0.040 |
Why?
|
| Health Services Research | 1 | 2003 | 180 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 1993 | 723 | 0.040 |
Why?
|
| Animal Testing Alternatives | 1 | 2001 | 3 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2003 | 216 | 0.040 |
Why?
|
| Decision Making | 1 | 2007 | 714 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2006 | 439 | 0.040 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 29 | 0.040 |
Why?
|
| Young Adult | 1 | 2015 | 10033 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2002 | 139 | 0.040 |
Why?
|
| Prevalence | 1 | 2008 | 2693 | 0.040 |
Why?
|
| Phenolsulfonphthalein | 1 | 2000 | 1 | 0.040 |
Why?
|
| Mass Screening | 1 | 1987 | 821 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2002 | 463 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 1287 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 43 | 0.040 |
Why?
|
| Bias | 1 | 2001 | 149 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2000 | 638 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 158 | 0.040 |
Why?
|
| Mental Recall | 1 | 2001 | 136 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2003 | 398 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4455 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2001 | 246 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2000 | 70 | 0.040 |
Why?
|
| Collagen | 2 | 2000 | 273 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 3 | 1985 | 195 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 554 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2000 | 35 | 0.040 |
Why?
|
| Age Factors | 2 | 2003 | 2818 | 0.040 |
Why?
|
| Cefazolin | 1 | 2000 | 19 | 0.040 |
Why?
|
| Adhesins, Bacterial | 1 | 2000 | 74 | 0.040 |
Why?
|
| Lacrimal Apparatus | 2 | 2000 | 124 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 386 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2001 | 364 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2004 | 942 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2003 | 448 | 0.040 |
Why?
|
| Wound Healing | 2 | 2000 | 486 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2000 | 146 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 2000 | 131 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 225 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 2 | 1997 | 44 | 0.040 |
Why?
|
| Actinomycetales Infections | 1 | 1979 | 14 | 0.040 |
Why?
|
| Mutation | 2 | 2010 | 6058 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 1991 | 235 | 0.040 |
Why?
|
| Buffers | 1 | 1998 | 27 | 0.040 |
Why?
|
| Charcoal | 1 | 1998 | 8 | 0.040 |
Why?
|
| Agar | 1 | 1998 | 17 | 0.040 |
Why?
|
| Yeasts | 1 | 1998 | 43 | 0.040 |
Why?
|
| Safety | 1 | 1999 | 214 | 0.040 |
Why?
|
| Simplexvirus | 2 | 1991 | 100 | 0.040 |
Why?
|
| Inflammation | 5 | 1988 | 1481 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2002 | 645 | 0.030 |
Why?
|
| Infant | 4 | 2004 | 13293 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1998 | 135 | 0.030 |
Why?
|
| Penicillins | 1 | 1998 | 154 | 0.030 |
Why?
|
| Naphazoline | 1 | 1997 | 2 | 0.030 |
Why?
|
| Nasal Decongestants | 1 | 1997 | 4 | 0.030 |
Why?
|
| Intraocular Pressure | 3 | 1982 | 107 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 71 | 0.030 |
Why?
|
| Fluorometholone | 1 | 1996 | 2 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1994 | 305 | 0.030 |
Why?
|
| Research Design | 2 | 1991 | 714 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2000 | 477 | 0.030 |
Why?
|
| Acute Disease | 4 | 1998 | 1152 | 0.030 |
Why?
|
| Regression Analysis | 2 | 1994 | 760 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 1996 | 29 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 1986 | 41 | 0.030 |
Why?
|
| Imidazoles | 1 | 1997 | 219 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2002 | 4057 | 0.030 |
Why?
|
| Cyclodextrins | 1 | 1995 | 4 | 0.030 |
Why?
|
| Mitomycins | 1 | 1995 | 5 | 0.030 |
Why?
|
| Internship and Residency | 1 | 1985 | 1221 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1996 | 83 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 257 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2010 | 8602 | 0.030 |
Why?
|
| Fundus Oculi | 1 | 1995 | 36 | 0.030 |
Why?
|
| Patient Compliance | 2 | 1994 | 462 | 0.030 |
Why?
|
| Cell Count | 2 | 1992 | 212 | 0.030 |
Why?
|
| Injections | 2 | 2006 | 109 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 1995 | 63 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 947 | 0.030 |
Why?
|
| Drug Carriers | 1 | 1995 | 119 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 134 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1994 | 562 | 0.020 |
Why?
|
| Blepharitis | 2 | 1997 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 3751 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 1995 | 667 | 0.020 |
Why?
|
| Vidarabine | 2 | 2004 | 91 | 0.020 |
Why?
|
| Graft Survival | 1 | 1995 | 459 | 0.020 |
Why?
|
| Suture Techniques | 1 | 2014 | 178 | 0.020 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 1992 | 13 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 193 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 2000 | 782 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1992 | 88 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 1604 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1996 | 848 | 0.020 |
Why?
|
| Species Specificity | 2 | 2000 | 470 | 0.020 |
Why?
|
| Cyclosporins | 2 | 1982 | 14 | 0.020 |
Why?
|
| Necrosis | 2 | 1995 | 192 | 0.020 |
Why?
|
| Staphylococcus | 1 | 1991 | 68 | 0.020 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1991 | 9 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 1229 | 0.020 |
Why?
|
| Americas | 1 | 1991 | 52 | 0.020 |
Why?
|
| Betaxolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Levobunolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 1991 | 50 | 0.020 |
Why?
|
| Africa | 1 | 1991 | 135 | 0.020 |
Why?
|
| Asia | 1 | 1991 | 123 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1991 | 37 | 0.020 |
Why?
|
| Australia | 1 | 1991 | 172 | 0.020 |
Why?
|
| Tears | 3 | 1987 | 185 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 223 | 0.020 |
Why?
|
| Europe | 1 | 1991 | 364 | 0.020 |
Why?
|
| Chondroitin | 1 | 1989 | 2 | 0.020 |
Why?
|
| HEPES | 1 | 1989 | 2 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 230 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1989 | 13 | 0.020 |
Why?
|
| Keratotomy, Radial | 1 | 1989 | 22 | 0.020 |
Why?
|
| Natamycin | 1 | 2009 | 5 | 0.020 |
Why?
|
| Descemet Membrane | 1 | 1989 | 11 | 0.020 |
Why?
|
| Saline Solution, Hypertonic | 1 | 1989 | 20 | 0.020 |
Why?
|
| Program Evaluation | 1 | 1991 | 445 | 0.020 |
Why?
|
| Lung | 1 | 1996 | 1531 | 0.020 |
Why?
|
| Penicillin G Benzathine | 1 | 1987 | 20 | 0.020 |
Why?
|
| Piperazines | 1 | 1989 | 265 | 0.020 |
Why?
|
| Ear Diseases | 1 | 1987 | 23 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 1987 | 87 | 0.020 |
Why?
|
| Image Enhancement | 1 | 1988 | 159 | 0.020 |
Why?
|
| Citrobacter | 1 | 1986 | 21 | 0.020 |
Why?
|
| Chlamydia trachomatis | 1 | 1986 | 28 | 0.010 |
Why?
|
| Cefuroxime | 1 | 2006 | 15 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1986 | 18 | 0.010 |
Why?
|
| Inclusion Bodies | 1 | 1986 | 38 | 0.010 |
Why?
|
| Fluorophotometry | 1 | 2006 | 31 | 0.010 |
Why?
|
| Anterior Chamber | 1 | 2006 | 26 | 0.010 |
Why?
|
| Ofloxacin | 1 | 2006 | 29 | 0.010 |
Why?
|
| Levofloxacin | 1 | 2006 | 49 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1986 | 54 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1986 | 57 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1987 | 124 | 0.010 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 1986 | 20 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1986 | 245 | 0.010 |
Why?
|
| Health Status | 1 | 2008 | 378 | 0.010 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1985 | 5 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2000 | 2061 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2008 | 394 | 0.010 |
Why?
|
| Aspergillus | 1 | 1985 | 26 | 0.010 |
Why?
|
| Texas | 1 | 1994 | 3661 | 0.010 |
Why?
|
| Clindamycin | 1 | 1985 | 40 | 0.010 |
Why?
|
| Drug Packaging | 1 | 1984 | 6 | 0.010 |
Why?
|
| Enterobacter | 1 | 1984 | 13 | 0.010 |
Why?
|
| Penicillin G | 2 | 1984 | 18 | 0.010 |
Why?
|
| Horses | 1 | 1985 | 94 | 0.010 |
Why?
|
| Staphylococcus epidermidis | 1 | 1984 | 39 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1986 | 344 | 0.010 |
Why?
|
| Cyclopentolate | 1 | 2004 | 4 | 0.010 |
Why?
|
| Tropicamide | 1 | 2004 | 4 | 0.010 |
Why?
|
| Mydriatics | 1 | 2004 | 13 | 0.010 |
Why?
|
| Amblyopia | 1 | 2004 | 33 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 41 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1986 | 145 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1986 | 261 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2006 | 181 | 0.010 |
Why?
|
| Electroretinography | 1 | 1984 | 96 | 0.010 |
Why?
|
| Pupil | 1 | 2004 | 44 | 0.010 |
Why?
|
| Neutrophils | 1 | 1986 | 371 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1984 | 238 | 0.010 |
Why?
|
| Mycetoma | 1 | 2003 | 3 | 0.010 |
Why?
|
| Voriconazole | 1 | 2003 | 29 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1987 | 475 | 0.010 |
Why?
|
| Lenses, Intraocular | 1 | 1985 | 218 | 0.010 |
Why?
|
| Epithelium, Corneal | 1 | 2004 | 173 | 0.010 |
Why?
|
| Clobetasol | 1 | 1981 | 3 | 0.010 |
Why?
|
| Choroiditis | 1 | 1981 | 1 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2001 | 49 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1984 | 254 | 0.010 |
Why?
|
| Steroids | 1 | 1982 | 168 | 0.010 |
Why?
|
| Florida | 1 | 2001 | 73 | 0.010 |
Why?
|
| Neisseriaceae | 1 | 1980 | 2 | 0.010 |
Why?
|
| Models, Anatomic | 1 | 2001 | 105 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 599 | 0.010 |
Why?
|
| Self Concept | 1 | 2001 | 156 | 0.010 |
Why?
|
| Cephalexin | 1 | 2000 | 7 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1981 | 250 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 1981 | 226 | 0.010 |
Why?
|
| Social Behavior | 1 | 2001 | 214 | 0.010 |
Why?
|
| Capsid | 1 | 2000 | 93 | 0.010 |
Why?
|
| Bacterial Adhesion | 1 | 2000 | 104 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2000 | 207 | 0.010 |
Why?
|
| Actinomycetales | 1 | 1979 | 3 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2000 | 336 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1997 | 94 | 0.010 |
Why?
|
| Biological Availability | 2 | 1987 | 135 | 0.010 |
Why?
|
| Nonprescription Drugs | 1 | 1997 | 57 | 0.010 |
Why?
|
| Protein Binding | 1 | 2000 | 1651 | 0.010 |
Why?
|
| Propoxycaine | 1 | 1996 | 2 | 0.010 |
Why?
|
| Procaine | 1 | 1996 | 12 | 0.010 |
Why?
|
| Self Medication | 1 | 1996 | 20 | 0.010 |
Why?
|
| Neuralgia | 2 | 1987 | 48 | 0.010 |
Why?
|
| Tetracaine | 1 | 1996 | 11 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1995 | 50 | 0.010 |
Why?
|
| Serotyping | 1 | 1994 | 170 | 0.010 |
Why?
|
| Disposable Equipment | 1 | 1993 | 15 | 0.010 |
Why?
|
| Patient Participation | 1 | 1996 | 253 | 0.010 |
Why?
|
| Beta Particles | 1 | 1991 | 1 | 0.010 |
Why?
|
| Strontium Radioisotopes | 1 | 1991 | 1 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 1991 | 13 | 0.010 |
Why?
|
| Cryosurgery | 1 | 1991 | 51 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1989 | 14 | 0.000 |
Why?
|
| Fixatives | 1 | 1989 | 14 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 808 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 115 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 181 | 0.000 |
Why?
|
| Parotid Gland | 1 | 1986 | 17 | 0.000 |
Why?
|
| Salivary Glands | 1 | 1986 | 35 | 0.000 |
Why?
|
| Sensation | 1 | 1987 | 46 | 0.000 |
Why?
|
| Organic Chemicals | 1 | 1986 | 58 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1986 | 122 | 0.000 |
Why?
|
| Herpesvirus 3, Human | 1 | 1985 | 29 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1989 | 905 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1986 | 303 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1985 | 141 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1986 | 436 | 0.000 |
Why?
|
| Pain | 1 | 1986 | 437 | 0.000 |
Why?
|
| Skin | 1 | 1986 | 543 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1981 | 33 | 0.000 |
Why?
|
| Rats | 1 | 1987 | 3368 | 0.000 |
Why?
|